Cardioprotection Induced by Activation of GPER in Ovariectomized Rats With Pulmonary Hypertension. (21st May 2018)

• Record Type: Journal Article
• Authors: Alencar, Allan K N; Montes, Guilherme C; Costa, Daniele G; Mendes, Luiza V P; Silva, Ananssa M S; Martinez, Sabrina T; Trachez, Margarete M; Cunha, Valéria do M N; Montagnoli, Tadeu L; Fraga, Aline G M; Wang, Hao; Groban, Leanne; Fraga, Carlos A M; Sudo, Roberto T; Zapata-Sudo, Gisele
• Is Part Of: Journals of gerontology. Volume 73:Number 9(2018:Sep.)
• Page Start: 1158
• Page End: 1166
• Publication Date: 2018-05-21
• Subjects: Estrogen -- Ovariectomy -- Cardiopulmonary system -- Right ventricle failure; Geriatrics -- Periodicals; Gerontology -- Periodicals; 618.97
• DOI: 10.1093/gerona/gly068
• Languages: English
• ISSNs: 1079-5006

Abstract

Abstract: Pulmonary hypertension (PH) is a disease of women (female-to-male ratio 4:1), and is associated with cardiac and skeletal muscle dysfunction. Herein, the activation of a new estrogen receptor (GPER) by the agonist G1 was evaluated in oophorectomized rats with monocrotaline (MCT)-induced PH. Depletion of estrogen was induced by bilateral oophorectomy (OVX) in Wistar rats. Experimental groups included SHAM or OVX rats that received a single intraperitoneal injection of MCT (60 mg/kg) for PH induction. Animals received s.c. injection of either vehicle or G1, a GPER agonist, (400 µg/kg/day) for 14 days after the onset of disease. Rats with PH exhibited exercise intolerance and cardiopulmonary alterations, including reduced pulmonary artery flow, biventricular remodeling, and left ventricular systolic and diastolic dysfunction. The magnitude of these PH-induced changes was significantly greater in OVX versus SHAM rats. G1 treatment reversed both cardiac and skeletal muscle functional aberrations caused by PH in OVX rats. G1 reversed PH-related cardiopulmonary dysfunction and exercise intolerance in female rats, a finding that may have important implications for the ongoing clinical evaluation of new drugs for the treatment of the disease in females after the loss of endogenous estrogens.